Iolanda Cirillo

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men
    Iolanda Cirillo
    Clinical Pharmacology, Johnson and Johnson Pharmaceutical Research and Development, L L C, 920 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 52:3478-83. 2008
  2. doi request reprint Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers
    Iolanda Cirillo
    J and J Pharmaceutical Research and Development LLC, Route 202, Raritan, NJ 08869 3509, USA
    J Clin Pharmacol 49:798-806. 2009
  3. doi request reprint Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis
    Iolanda Cirillo
    Clinical Pharmacology Leader, J and J Pharmaceutical Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869 3509, USA
    J Clin Pharmacol 52:1645-53. 2012
  4. pmc Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy
    Mahesh N Samtani
    Clinical Pharmacology, Janssen Research and Development, L L C, 920 Route 202, Raritan, NJ 08869, USA
    ISRN Pharmacol 2012:782656. 2012
  5. pmc Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem
    Iolanda Cirillo
    Clinical Pharmacology, Johnson and Johnson Pharmaceutical Research and Development, L L C, 920 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 55:1187-93. 2011

Detail Information

Publications5

  1. pmc Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men
    Iolanda Cirillo
    Clinical Pharmacology, Johnson and Johnson Pharmaceutical Research and Development, L L C, 920 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 52:3478-83. 2008
    ..These results show that doripenem is predominantly eliminated in urine as unchanged drug, with only a fraction metabolized to doripenem-M-1 and other minor metabolites...
  2. doi request reprint Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers
    Iolanda Cirillo
    J and J Pharmaceutical Research and Development LLC, Route 202, Raritan, NJ 08869 3509, USA
    J Clin Pharmacol 49:798-806. 2009
    ..These results, along with the stability profile of doripenem, support its use as a prolonged infusion. All regimens of doripenem were safe and well tolerated...
  3. doi request reprint Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis
    Iolanda Cirillo
    Clinical Pharmacology Leader, J and J Pharmaceutical Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869 3509, USA
    J Clin Pharmacol 52:1645-53. 2012
    ..The pharmacokinetics of doripenem in adult patients with CF are similar to those from adult HVs, noting some differences in the disposition when comparing body mass index-adjusted pharmacokinetic parameters...
  4. pmc Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy
    Mahesh N Samtani
    Clinical Pharmacology, Janssen Research and Development, L L C, 920 Route 202, Raritan, NJ 08869, USA
    ISRN Pharmacol 2012:782656. 2012
    ..This work was conducted to fulfill a health authority request and resulted in the addition of dosing recommendations to the Doribax Summary of Product Characteristics...
  5. pmc Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem
    Iolanda Cirillo
    Clinical Pharmacology, Johnson and Johnson Pharmaceutical Research and Development, L L C, 920 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 55:1187-93. 2011
    ..Doripenem dosage regimens for patients receiving CRRT thus need to be adjusted...